Stock Options for Directors, Executive Officers and Employees
First written in FY2016. 11 of 13 entries say "Advanced", first in FY2018. Latest entry: FY2026.
106 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Exercised: 119,000 25,400; expired: 3,000 800; unexercised balance: 91,000 37,700」
Under the 2022 fiscal-year first and second stock acquisition rights, 119,000 shares and 25,400 shares, respectively, were exercised, leaving year-end unexercised balances of 91,000 shares and 37,700 shares, respectively. - FY2026-H1AdvancedAnnual report
「The company has determined the exercisable percentages of the stock acquisition rights as set out below, based on the targets in its medium-term management plan: consolidated net sales of ¥70 billion, a consolidated ordinary profit margin of 5.0% and consolidated return on equity of 10.0% for the fiscal year ending March 2030 (the 60th fiscal year).」
The company issued the 2025 fiscal-year first and second stock acquisition rights and granted them to directors, executive officers, executive advisers, employees and others. In addition, the exercisable percentage of the first stock acquisition rights was linked to the achievement of ¥70 billion in net sales, a 5.0% ordinary profit margin and ROE of 10.0% for the fiscal year ending March 2030. - FY2025AdvancedAnnual report
「The company has determined the exercisable percentages of the stock acquisition rights as set out below, based on the targets in its medium-term management plan: consolidated net sales of ¥70 billion, a consolidated ordinary profit margin of 5.0% and consolidated return on equity of 10.0% for the fiscal year ending March 2030 (the 60th fiscal year).」
The company established the 2025 fiscal-year first stock acquisition rights and linked the exercisable percentages to the achievement of ¥70 billion in net sales, a 5.0% ordinary profit margin and ROE of 10.0% for the fiscal year ending March 2030. - FY2024AdvancedAnnual report
「Exercised: 8,600 8,600; expired: 9,400 23,500; unexercised balance: — —」
Under the 2018 fiscal-year first and second stock acquisition rights, 8,600 shares were exercised under each series, while 9,400 shares and 23,500 shares, respectively, expired, leaving no unexercised balance under either series. - FY2023AdvancedAnnual report
「Exercised: 18,000 15,300 6,200; expired: 14,900 — 900; unexercised balance: — 18,000 32,100」
Under the 2015 fiscal-year stock acquisition rights, 18,000 shares were exercised and 14,900 shares expired. Under the 2018 fiscal-year first and second stock acquisition rights, 15,300 shares and 6,200 shares, respectively, were exercised. The company also granted 216,000 shares under the 2022 fiscal-year first stock acquisition rights and 74,900 shares under the second. - FY2022AdvancedAnnual report
「The company has determined the exercisable percentages of the stock acquisition rights as set out below, based on the targets in its medium-term management plan: consolidated net sales of ¥55 billion and a consolidated ordinary profit margin of 3.3% for the fiscal year ending March 2025 (the 55th fiscal year), designated as Performance Target A and Performance Target B.」
The company granted 222,000 shares under the 2022 fiscal-year first stock acquisition rights to 63 directors, executive officers and employees, and 80,200 shares under the second stock acquisition rights to 446 employees. The exercisable percentages were linked to the achievement of ¥55 billion in net sales and a 3.3% ordinary profit margin for the fiscal year ending March 2025. - FY2021AdvancedAnnual report
「Exercised: 19,500 50,300 14,700; expired: — 93,300 1,100; unexercised balance: 46,500 46,100 49,600」
Under the 2015 fiscal-year stock acquisition rights, 19,500 shares were exercised; under the 2018 fiscal-year first and second stock acquisition rights, 50,300 shares and 14,700 shares, respectively, were exercised. Expirations also occurred under the 2018 fiscal-year first and second stock acquisition rights, leaving year-end unexercised balances of 46,100 shares and 49,600 shares, respectively. - FY2020AdvancedAnnual report
「Exercised: 1,500 shares; expired: 1,000 shares; unexercised balance: 66,000 shares」
During the fiscal year, 1,500 shares under the 2015 fiscal-year stock acquisition rights were exercised and 1,000 shares expired. The unexercised balance was 66,000 shares. - FY2019AdvancedAnnual report
「2015 fiscal-year stock acquisition rights: exercised, 24,400 shares; unexercised balance, 68,500 shares. 2018 fiscal-year first stock acquisition rights: unvested balance, 191,200 shares. 2018 fiscal-year second stock acquisition rights: unvested balance, 71,700 shares.」
The company confirmed the exercise of 24,400 shares under the 2015 fiscal-year stock acquisition rights. The unvested balances of the 2018 fiscal-year first and second stock acquisition rights were 191,200 shares and 71,700 shares, respectively. - FY2019-Q1AdvancedAnnual report
「With respect to the equity-settled stock options (stock acquisition rights) allocated to the company's directors (excluding outside directors), executive officers and employees, as resolved at the Board of Directors meeting held on 28 June 2018, the items that had remained undecided were finalized as follows on 27 July 2018, the allocation date.」
The allocation details for the 2018 fiscal-year first and second stock acquisition rights, including grants to directors, executive officers and employees and to 425 employees, a total of 268,800 shares, and exercise periods from July 2020 to June 2023, were finalized. The first series is linked to the achievement of ¥55 billion in net sales and a 3.0% ordinary profit margin. - FY2018AdvancedAnnual report
「The company has determined the exercisable percentages of the stock acquisition rights as set out below, based on the targets in its medium-term management plan: consolidated net sales of ¥55 billion and a consolidated ordinary profit margin of 3.0% for the fiscal year ending March 2020 (the 50th fiscal year).」
In addition to the vesting and exercise of the 2015 fiscal-year stock acquisition rights, the company issued 2018 fiscal-year stock acquisition rights for directors, executive officers and employees, with some of them linked to the achievement of ¥55 billion in net sales and a 3.0% ordinary profit margin under the medium-term management plan. - FY2017RestatedAnnual report
「The system was approved by resolution at the Board of Directors meeting held on 26 June 2015 pursuant to the Companies Act.」
The company continues to disclose its stock option system for directors, executive officers and employees. At the end of the fiscal year, 214,000 shares remained unvested, and the exercise period is from 14 July 2017 to 13 July 2022. - FY2016First statedAnnual report
「The system was approved by resolution at the Board of Directors meeting held on 26 June 2015 pursuant to the Companies Act.」
217,000 common shares were granted to 5 directors and 114 employees. The exercise period is from 14 July 2017 to 13 July 2022.